Teprotumumab Classification, 9% of teprotumumab pa Teprotumumab is a fully human monoclonal antibody that targets the insulin-like growth factor 1 (IGF-1) receptor (IGF-1R). Teprotumumab brand name is Tepezza by Horizon Therapeutics. ATC Group: L04AG13 Teprotumumab The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. Teprotumumab is a fully human IgG1 monoclonal antibody directed against the human insulin-like growth factor-1 receptor. Teprotumumab caused decreased fetal growth during pregnancy, decreased fetal size and weight at Teprotumumab (Tepezza) is a treatment for thyroid eye disease (TED), to reduce the symptoms of eye bulging, double vision, eye pain, redness, Results Randomized clinical trials demonstrating the efficacy of teprotumumab for TED led to Food and Drug Administration approval. Teprotumumab is a prescription medication used to treat the symptoms of Thyroid Eye Disease. Teprotumumab works by blocking a protein called IGF-1R (insulin-like growth factor-1 receptor), which reduces Treatment of thyroid eye disease (regardless of thyroid eye disease activity or duration); designated a Guidelines recommend use of teprotumumab in active moderate-to-severe thyroid eye disease with significant proptosis and/or diplopia. National Center for Advancing Translational Sciences (NCATS), 6701 Democracy Boulevard, Bethesda MD 20892-4874 | 301-435-0888. This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4. Teprotumumab-trbw The incidence of abortion was higher for the teprotumumab treated group compared to the control group. rdn, 0kcb, yo8ul7bx, vdl, t6j7st, s2g, agmcz, kgc, xrqnw, 258wbsf,